Skip to content

Study on the Efficacy of Ruyi Zhenbao Tablets in Acute Ischemic Stroke

Study on the Efficacy of Ruyi Zhenbao Tablets in Acute Ischemic Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073074
Enrollment
Unknown
Registered
2023-06-30
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Intervention group:Pharmacological intervention with Yaoyi Zhenbao Tablets.
control group:placebo

Sponsors

The Second People’s Hospital of Yuhuan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The goal is to enroll 150 patients with acute ischemic stroke who will be admitted to our hospital from July 1st, 2023, to July 31st, 2024. The inclusion criteria are as follows: (1) meeting the diagnosis criteria for stroke; (2) onset of symptoms within 72 hours; (3) age of 18 or above; (4) clear consciousness, without significant cognitive impairments, and willing to cooperate with examinations and treatments; (5) signed informed consent form, indicating their voluntary participation in the research.

Exclusion criteria

Exclusion criteria: (1) Patients with brain tumors, traumatic brain injuries, parasitic diseases, metabolic disorders, and other diseases. (2) Patients with significant cardiovascular, liver, kidney, hematopoietic, endocrine system, or gastrointestinal diseases. (3) Patients with allergies to the experimental drugs or multiple medications.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale(mRS);

Countries

china

Contacts

Public Contactshiqin chen

The Second People’s Hospital of Yuhuan

13967685809@163.com+86 139 6768 5809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026